Mercks $620 million Rosetta acquisition in May was great fodder for the industry rumor mill. It seems Mercks CEO Raymond Gilmartin joined Microsofts board just two weeks before the acquisition. Meanwhile, Microsoft has been making noise about pursuing pharma industry business. And a member of Rosettas board is from Vulcan Ventures, the VC outfit run by Microsoft cofounder Paul Allen. What of this tangled web, you ask?